^○Takashi Yamamoto (Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University)

^○Miki Nakajima (Faculty of Pharmaceutical Sciences, Kanazawa University)

^○Norihiko Iwazaki (DMPK Research Laboratories, Mitsubishi Tanabe Pharma CorporationConsortium for Safety Assessment using Human iPS Cells)

^○Yasuyuki Sakai (Department of Chemical System Engineering, Graduate School of Engineering, University of Tokyo)

^○Kazuo Takayama ^1,2,3, Tatsuya Ozawa ^1,2, Fuminori Sakurai ¹, Masashi Tachibana ¹, Hiroyuki Mizuguchi ^1,2,3,4 (1.Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, 2.Laboratory of Hepatocyte Regulation, National Institutes of Biomedical Innovation, Health and Nutrition, 3.iPS Cell-based Research Project on Hepatic Toxicity and Metabolism, Graduate School of Pharmaceutical Sciences, Osaka University, 4.Global Center for Medical Engineering and Informatics, Osaka University)

^○Kosuke Yokobori , Kaoru Kobayashi , Ikuko Azuma , Kan Chiba (Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University)